Evergreen Wealth Management LLC Buys 84 Shares of Amgen Inc. (NASDAQ:AMGN)

Evergreen Wealth Management LLC grew its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 1.7% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,892 shares of the medical research company’s stock after purchasing an additional 84 shares during the quarter. Evergreen Wealth Management LLC’s holdings in Amgen were worth $1,409,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. OFI Invest Asset Management acquired a new position in Amgen during the third quarter worth $26,000. Briaud Financial Planning Inc bought a new position in shares of Amgen in the 3rd quarter valued at about $26,000. BOK Financial Private Wealth Inc. acquired a new position in shares of Amgen during the 4th quarter worth about $29,000. Providence Capital Advisors LLC acquired a new position in shares of Amgen during the 3rd quarter worth about $30,000. Finally, Planned Solutions Inc. bought a new stake in shares of Amgen in the 4th quarter valued at about $30,000. Institutional investors own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. SVB Leerink downgraded Amgen from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $324.00 to $318.00 in a research report on Wednesday, February 7th. StockNews.com raised Amgen from a “hold” rating to a “buy” rating in a report on Friday. TD Cowen cut their price target on Amgen from $370.00 to $360.00 and set a “buy” rating for the company in a report on Wednesday, April 17th. Royal Bank of Canada decreased their price objective on shares of Amgen from $332.00 to $328.00 and set an “outperform” rating on the stock in a report on Friday. Finally, The Goldman Sachs Group raised their target price on shares of Amgen from $313.00 to $350.00 and gave the stock a “buy” rating in a research note on Wednesday, February 7th. Ten analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $305.05.

Amgen Price Performance

NASDAQ AMGN traded up $32.90 during midday trading on Friday, hitting $311.29. The company had a trading volume of 9,644,682 shares, compared to its average volume of 2,279,398. The company has a market capitalization of $166.97 billion, a PE ratio of 44.47, a P/E/G ratio of 3.01 and a beta of 0.60. Amgen Inc. has a twelve month low of $211.71 and a twelve month high of $329.72. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 10.14. The firm has a 50-day moving average price of $274.95 and a 200-day moving average price of $281.46.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Thursday, May 2nd. The medical research company reported $3.96 EPS for the quarter, beating analysts’ consensus estimates of $3.76 by $0.20. The business had revenue of $7.45 billion during the quarter, compared to the consensus estimate of $7.45 billion. Amgen had a return on equity of 145.62% and a net margin of 12.74%. Amgen’s revenue for the quarter was up 22.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.98 earnings per share. As a group, analysts anticipate that Amgen Inc. will post 19.46 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be given a dividend of $2.25 per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $9.00 annualized dividend and a dividend yield of 2.89%. Amgen’s dividend payout ratio is 128.57%.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 2,117 shares of the business’s stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $313.09, for a total transaction of $662,811.53. Following the completion of the transaction, the senior vice president now owns 9,883 shares of the company’s stock, valued at $3,094,268.47. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.46% of the stock is currently owned by company insiders.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.